Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Sep 11;16(9):328. doi: 10.3390/md16090328

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Effects of PYCP supplementation on the autophagy-lysosome system in gastrocnemius muscle. (A,B) Cathepsin-L mRNA and protein levels were assessed with real-time PCR and Western blot analysis; (C,D) protein levels of autophagy-related genes (i.e., LC3-I/LC3-II, BECN1, ATG5, ATG7, ATG12, and p62/SQSTM1) assessed by Western blot analysis. GAPDH was used as an internal standard. Data represent mean ± standard deviation of three independent experiments (n = 5/group). * p < 0.05, ** p < 0.01, *** p < 0.001 vs. the corresponding control group; ^# p < 0.05, ^## p < 0.01, ^### p < 0.001 vs. the corresponding DEX-only treatment group.

Effects of PYCP supplementation on the autophagy-lysosome system in gastrocnemius muscle. (A,B) Cathepsin-L mRNA and protein levels were assessed with real-time PCR and Western blot analysis; (C,D) protein levels of autophagy-related genes (i.e., LC3-I/LC3-II, BECN1, ATG5, ATG7, ATG12, and p62/SQSTM1) assessed by Western blot analysis. GAPDH was used as an internal standard. Data represent mean ± standard deviation of three independent experiments (n = 5/group). * p < 0.05, ** p < 0.01, *** p < 0.001 vs. the corresponding control group; ^# p < 0.05, ^## p < 0.01, ^### p < 0.001 vs. the corresponding DEX-only treatment group.